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Background and aim of the work: Idiopathic pulmonary fibrosis (IPF) is a progressive disease
with high mortality rates and a median survival of 2e3 years from time of diagnosis. The prog-
nosis for any individual patient, however, is variable. To elucidate the clinical significance of 6-
min walking test (6-MWT) in patients with IPF, we sought to assess the relationship between
distance walked and desaturation during this test and pulmonary function tests (PFTs). We
also evaluate the prognostic value of 6-MWT in comparison with PFTs at baseline and during
follow-up.
Methods: The clinical data of 44 patients with IPF were retrospectively analysed. Twenty-nine
patients had an additional evaluation after 12 month of follow-up.
Results: Distance walked in 6 min was independently related to mortality by multivariate anal-
ysis. Patients walking less then 212 m had a significantly lower survival than those walking
farther, assessed by KaplaneMeier survival curves (log-rank test, p< 0.036). During a mean
follow-up period of 19.8 months (range 3.2e46.4), 11 patients died of causes related to
disease. Changes in meters walked at 12 months evaluation were also predictive of survival
(pZ 0.05).
Conclusions: These results confirm that in IPF distance walked in 6 min is independent associ-
ated with mortality.
ª 2008 Elsevier Ltd. All rights reserved.02) 85994580; fax: þ39 (02)
.it (S. Harari).
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Idiopathic pulmonary fibrosis (IPF) is associated with
significant morbidity and mortality and with poor response
to traditional therapies.1e5 Median survival is generally
reported as 2e3 years from time of diagnosis.1.
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substantial heterogeneity in survival among patients and it
has proven to be difficult to predict survival time in indi-
vidual patients.1,6 Additional predictors of survival are
important to help patients and physicians to stratify risks
and benefits of therapeutic approaches, including experi-
mental protocols, cytotoxic therapies, and lung trans-
plantation.7,8 Recent efforts to predict prognosis for
individuals with IPF have focused on demographic (age,
smoking, sex), baseline physiologic parameters (diffusion
capacity for carbon monoxide [DLCO], FVC, exercise PaO2,
desaturation on 6-MWT), changes of physiologic tests at 6e
12 months (dyspnoea score, FVC, TLC, DLCO), radiographic
(amount of fibrosis), and histopathologic features (fibro-
blastic foci).9e15
Most patients with IPF experience exercise dyspnoea as
the first symptom and a key feature is impaired to the gas
exchange that worsens with exercise.1,16e18 Clinical exer-
cise testing using cycle ergometer or treadmill protocols
has been used in patients with interstitial lung diseases,
and most showed a marked drop in oxygen saturation during
exercise.16,19e21 However, these forms of exercise can be
unfamiliar to some patients. The 6-MWT is a simple test to
evaluate desaturation22,23; it is a more familiar form of
exercise for patients and more relevant to their everyday
live and can be performed even by patients with advanced
pulmonary or cardiac diseases.24 Test is very simple,
requires inexpensive equipment, and is reproducible.17 In
addition, it is considered to be safe because patients are
self-limited during exercise. The 6-MWT has been shown to
have prognostic value in various forms of advanced lung
disease.25e28
In the present study, we sought: (1) to assess the rela-
tion between distance walked and desaturation during 6-
MWT and PFTs, (2) to evaluate prognostic value of 6-MWT in
comparison with functional parameters at baseline evalu-
ation and (3) to investigate the prognostic value of changes
over time of 6-MWT and PFTs variables.
We hypothesized that 6-MWT and its changes during
follow-up may provide more reliable and potent prediction
of survival than baseline functional evaluation alone.
Some of the results of this study have been previously
reported in abstract form.29
Methods
Study population
Patients with a clinicaleradiological or a histological diag-
nosis of IPF according to the American Thoracic Society/
European Respiratory Society criteria1 who underwent a 6-
MWT on room air from January 2000 to December 2004
constituted the study group.
Clinical data and survival status were obtained from
medical records. Patients with an underlying connective
tissue disorder, exposure to environmental agents or drugs
known to cause pulmonary fibrosis, or other underlying
disorders known to cause pulmonary fibrosis were excluded
from the study. This study considered patients referred to
U.O. di Pneumologia, Ospedale S. Giuseppe, Milan. All
subjects had a complete clinical, radiological (high-resolutioncomputed tomography examination were performed in all
patients) and lung function evaluation. Moreover, all patients
underwent at baseline evaluation on echocardiographic
examination.
Surgical lung biopsies of patients with histological diag-
nosis were all reviewed by our pathologists.
All examinations performed were part of routine
screening and follow-up evaluations in our hospital, inde-
pendently from patients participation in this study.
PFTs and 6-MWT
All patients underwent PFTs and gas exchange evalua-
tions. Lung volumes, flow rates, and DLCO were measured
using a plethysmographic technique (SensorMedics; Yorba
Linda, CA), and corrected for temperature and baro-
metric pressure, according to the American Thoracic
Society recommendations.30e33 The single-breath DLCO
was measured according to the American Thoracic Society
recommendations and was corrected for haemoglobin
concentration.34e36
The 6-MWT was performed by a trained technician.37,38
Briefly, patients walked on level ground using standardized
instructions, including to walk ‘‘briskly’’ and as far as
possible, but not to run, for 6 min. Percutaneous arterial
saturation was assessed at baseline and during the test by
a continuous pulse oximeter (Nellcore; Pleasanton, CA)
using a finger sensor. If the resting saturation was less than
90% on room air, patients were not considered eligible for
room air 6-MWT. The 6-MWTs were symptom limited, so
patients were allowed to stop if necessary, though they
were instructed to resume walking as soon as possible. The
test was stopped for safety purposes if the arterial oxygen
saturation (SaO2) dropped to <86%. Baseline percentage of
SaO2 (SaO2-rest), lowest SaO2 measured during exercise
(SaO2-exercise), and the variation in SaO2 from rest to
exercise (SaO2-rest e SaO2-exerciseZDSaO2) reported as
decrease in units of percentage saturation (1%Z 1 U) and
the distance walked (in meters) were measured and
recorded.
Statistical methods
Continuous variables are presented either as mean
standard error (SE) or as median and interquartile range
(IQR) when the normality assumptions of the distribution
were not satisfied. Counts and percentages are given for
categorical variables. Relationships between parameters of
the 6-MWT and pulmonary function were assessed with
Spearman rank correlation coefficients.
The optimal cut-off value for distance walked during 6-
MWT to detect mortality was assessed using the receiver
operating characteristics (ROC).
Cox proportional hazards model was used to examine the
univariate relationship between 6-MWT parameters
measured at the time of the initial diagnosis (walking
distance, desaturation on 6-MWT) and mortality. Multivar-
iate Cox model was then performed for each parameter
separately, adjusting for covariates clinically and statisti-
cally significant such as age and sex. Hazard ratios and 95%
confidence intervals are presented. An additional evaluation
Table 2 Physiologic features and 6-MWT parameters of
study patients.
Characteristic Value (median IQR)
VC, L 2.26 1.19
VC, % predicted 80.5% 40
FVC, L 2.06 1.15
FVC, % predicted 74.5% 37
DLCO, (mL/min/mmHg) 11.5 7.8
DLCO, % predicted 52.5% 29.5
PaO2 75.9 14
Meters walked 240 300
Sat.O2-rest 95 2
Sat.O2-exercise 89 7
DSat.O2 7 6
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between 12 months and baseline were calculated and their
prognostic significance on mortality was evaluated in
a multivariate Cox model adjusting for their respective
baseline value.
KaplaneMeier curves are presented to analyse the time
for death from the time of initial diagnosis according to the
distance walked during 6-MWT. The two survival distribu-
tions were compared by means of the log-rank test. The
statistical significance level was set at p 0.05. SAS soft-
ware (SAS Institute, Cary, NC) and SPSS was used for
analyses.
Results
Of the 61 patients who underwent 6-MWT during the study
period, 17 were excluded, as their resting saturations was
less than 90%, therefore they did not undergo a room air 6-
MWT.
Forty-four study patients included 23 men and 21 women
with a mean age at presentation of 61.9 1.5 year. Nine-
teen patients (43%) had histological diagnosis (surgical lung
biopsies).
Thirty-five patients received treatment during the study
period either with corticosteroids alone (nZ 15) or corti-
costeroids and cyclophosphamide or azathioprine (nZ 20).
Eight patients were treated with prednisolone and cyclo-
phosphamide and 5 of this were alive on follow-up. Twelve
patients were treated with prednisolone and azathioprine
and 8 were alive on follow-up; 9 patients had no therapy.
Their clinical and physiologic data are summarized in
Tables 1 and 2.
During a mean follow-up period of 19.8 months (range
3.2e46.4), 11 of the 44 patients (25%) died for causes
related to disease; 3 patients fullfill the criteria for acute
exacerbation of disease.
Meters walked, SaO2-exercise and DSaO2 on 6-MWT
correlated with principal pulmonary functional parameters
(VC, FVC and DLCO) (Table 3).Table 1 Demographic features of study patients.
Characteristic Value (%)
Age, year (mean SE) 61.9 1.5
Sex
Male (%) 23 (52)
Female (%) 21 (48)
Smoking status
Never (%) 29 (66)
Former (%) 12 (27)
Current (%) 3 (7)
Treatment
None (%) 9 (20.5)
Corticosteroid alone (%) 15 (34.1)
Corticosteroid/cytotoxic agent combined (%) 20 (45.4)
Diagnosis
Clinicaleradiological (%) 25 (57)
Histological (%) 19 (43)At time of presentation, multivariate analysis showed
that VC (HR, 0.319; 95% CI, 0.105e0.967; pZ 0.04), DLCO
(HR, 0.723; 95% CI, 0.548e0.954; pZ 0.02) and meters
walked on 6-MWT (HR, 0.995; 95% CI, 0.99e0.999; pZ 0.03)
were independent risk factors for increased mortality in
this group of patients. FVC did not reach statistical signifi-
cance (pZ 0.06) (Table 4).
Median of 6-MWT distance walked was 375 m (q1 200 m,
q3 425 m, minimum 75 m) for 33 patients alive on follow-up
and 200 m (q1 75 m, q3 400 m, minimum 50 m) for 11
patients died (Fig. 1). KaplaneMeier survival curves grou-
ped according to ROC cut-off value of distance walked in
6 min demonstrated that patients walking less than 212 m
had a significantly lower survival rate than those walking
farther (log-rank test, p< 0.036, Fig. 2). The area under
the ROC curve was 0.64. The specificity and sensitivity at
the rating equal to 212 m was, respectively, 0.74 and 0.6.
Desaturation on 6-MWTwas not predictive of mortality in
multivariate analysis.
On baseline echocardiography only 3 patients (6.8%) had
systolic pulmonary arterial pressure over 40 mmHg.
Twenty-nine patients had an additional evaluation after
12 month of follow-up. Change in meters walked on 6-MWT
over 12 months was predictive of mortality and remained so
after adjusting for baseline value (HR, 0.994; 95% CI,
0.988e1, pZ 0.05). Another parameter which changes over
12 months was predictive of mortality was Sat.O2-rest (HR,
0.25; 95% CI, 0.075e0.837, pZ 0.02). The changes of FVC
and DLCO over 12 months were not statistically significant
in predicting patients survival (pZ 0.06) (Table 5).Table 3 Correlation between physiologic and 6-MWT
parameters.
Meters
walked
Sat.O2-rest Sat.O2-exercise DSat.O2
VC rZ 0.39 rZ 0.38 rZ 0.39 rZ0.38
pZ 0.02 pZ 0.03 pZ 0.02 pZ 0.02
FVC rZ 0.40 rZ 0.46 rZ 0.39 rZ0.39
pZ 0.01 pZ 0.007 pZ 0.02 pZ 0.02
DLCO rZ 0.42 rZ 0.17 rZ 0.37 rZ0.47
pZ 0.01 pZ 0.36 pZ 0.04 pZ 0.007
Table 4 Multivariate analysis (adjusted for age and sex
only) of physiologic and 6-MWT parameters associated with
mortality in IPF.
Variable Hazard
ratio (HR)
95% CI p Value
Age 0.985 0.910e1.067 0.7117
Sex 3.174 0.780e12.971 0.1067
Meters walked 0.995 0.990e0.999 0.0308
Sat.O2-rest 0.816 0.537e1.241 0.3416
Sat.O2-exercise 0.856 0.709e1.033 0.1052
DSat.O2 1.185 0.958e1.466 0.1177
VC (L) 0.319 0.105e0.967 0.0435
FVC (L) 0.365 0.124e1.078 0.0681
DLCO (mL/min/mmHg) 0.723 0.548e0.954 0.0219
PaO2 (mmHg) 0.953 0.903e1.007 0.0857
Definition of abbreviation: CIZ confidence interval and
LZ liter.
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Figure 2 KaplaneMeier survival curves according to the
distance walked during 6-MWT in patients with IPF. Patients
walking <212m had a significantly lower survival rate than
those walking farther (log-rank test, pZ 0.036).
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CT scan was not evaluated in this study.
Discussion
In this study, we demonstrated that distance walked during
6-MWT was significantly correlated with pulmonary func-
tional parameters (DLCO, VC, FVC). We also demonstrated
that distance walked in 6 min was independently related to
mortality in IPF and patients walking less than 212 m had
a significantly lower survival rate than those walking farther
as assessed by KaplaneMeier survival curves; 212 m in our
study group identified a cut-off distance with a bad prog-
nosis and the use of a change in meters walked as
a continuous variable confirms the ability of distance
walked to predict a less favourable outcome. Thus, our
data confirm recent observation that distance walked
during 6-MWT may serve as prognostic indicator in IPF,
which may complement other prognostic markers. In our
study desaturation on 6-MWT was not predictive of
mortality in multivariate analysis.Figure 1 Distance walked expressed in meters according to
patient’s outcome.IPF is a progressive disease with high mortality rates and
median survival of 2e3 years from time of diagnosis.1,3,9
However, the disease course for individual patients with UIP
can vary greatly. Although the typically poor prognosis of
IPF and the relative inefficacy of current therapies are
broadly understood, highly variable rates of progression
among individual patients remain both common and enig-
matic. Therefore, developing an improved understanding of
the predictors of progression and survival is critical.39
Despite the numerous variables used in monitoring this
disease, none have consistently proven to be a reliable
marker of disease progression or risk of death. Pulmonary
function evaluation at presentation is disappointingly
imprecise, prognostically.15,40,41 Change in FVC and DLCO
are today considered markers of disease progression but
patients with stable spirometric indices are not without risk
of dying; therefore, stability of PFTs does not necessarily
translate to stability of the disease. The 6-MWT has been
shown to correlate with function and outcomes in patients
with numerous advanced diseases.25e28 In our study DLCO
together with VC and FVC correlated with various param-
eters of 6-MWT (distance walked, SaO2-exercise andTable 5 Multivariate analysis (adjusted for age and sex
only) of physiologic and 6-MWT parameters variation at 12
months follow-up evaluation associated with mortality in
IPF.
Variable
(change 12 months
e basal value)
Hazard
ratio (HR)
95% CI p Value
Meters walked 0.994 0.988e1 0.05
Sat.O2-rest 0.25 0.075e0.837 0.02
Sat.O2-exercise 0.831 0.614e1.124 0.2294
DSat.O2 1.04 0.774e1.399 0.7926
VC (L) 0.165 0.011e2.503 0.19
FVC (L) 0.142 0.018e1.1 0.06
DLCO
(mL/min/mmHg)
0.49 0.232e1.036 0.06
PaO2 (mmHg) 0.954 0.889e1.023 1.1832
Definition of abbreviation: CIZ confidence interval and
LZ liter.
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of lung function: it provides a functional measurement of
the patient’s overall cardiopulmonary reserve. As such, it
may also account for other important prognostic parame-
ters not measured by standard PFTs, such as the effect of
pulmonary hypertension.7,42 However, only few data are
available regarding clinical significance of 6-MWT in
patients with IPF. Lama et al.14 demonstrate a strong
correlation of measures of fall in saturation on 6-MWT and
survival independent of the format used to define desatu-
ration. In our study, in contrast with Lama et al.14, desa-
turation on 6-MWT was not predictive of mortality in
multivariate analysis. This difference may be in part
explained by the format used to define desaturation in
these two studies. The relatively small number of cases in
our study may also have been a factor. This study included
only patients who had 6-MWT in room air and thus had
a selection bias. However, the causes for the discrepancy
between our study and Lama et al. are not clear.
Although the role of 6-MWT in risk-stratifying potential
lung transplant recipients is uncertain, the 6-MWT may yet
play an important role in the assessment of selected groups
of patients with IPF. Recently published guidelines on
selection and evaluation for lung transplantation in IPF
patients consider decrease of saturation below 88% during
6-MWT an important prognostic parameter.43 Recently,
Lederer et al.44 reported that lower 6-MWT distance in 454
patients in waiting list for lung transplantation was strongly
and independently associated with an increased mortality
rate. In this study patients walking less than 207 m had
a more than fourfold greater mortality rate than those
walking 207 m or more. Our observation provides support
for this data. Nevertheless, populations in these two
studies are very different: our patients are older but with
less severe disease, 6-MWT was always performed at the
same institution by trained nurses and with a strict
protocol, only patients that had a 6-MWT in room air were
considered and finally an analysis of the possible correla-
tion with PFT was also performed whereas only correlation
with FVC was performed in Lederers’ study. Patients with
IPF referred and listed for lung transplantation are
a distinct cohort; extrapolation of survival analyses from
these patients in another context may not be appropriate.
The very similar conclusions of our and Lederer’s studies
confirm the prognostic significance of distance walked on 6-
MWT in IPF patients. Our data suggests that such a reason-
able 6-MWT distance ambulated ‘‘screening’’ threshold
may be 212 m or less: 2.7-year survival rate of IPF patients
who walked <212 m was 27% compared with 54% in patients
who walked 212 m. Within-subject reproducibility of data
is a crucial consideration. Serial trends in indices with low
‘‘measurement noise’’ can be interpreted with greater
confidence.17 A recent study has showed that 6-MWT
distance is highly reproducible in fibrotic idiopathic inter-
stitial pneumonia, more then desaturation.17 This obser-
vation supports the importance of our data.
DLCO and VC correlate with mortality in multivariate
models; FVC did not reach statistical significance
(pZ 0.06), however, this is possible due to the limited
number of patients considered in our study population that
may have limited our ability to detect statistically signifi-
cant value in predicting mortality.A further novel aspect of our study is that change in
distance walked on 6-MWT over 12 months is predictive of
survival. Importantly, changes in this variable predict
survival even after adjustment for the baseline value,
suggesting that the rate of progression, independent of the
initial degree of disability, is important for determining
prognosis. In our study for each unitary decrease in meters
walked at 12 months observation, mortality increased by
1%. The only physiologic parameter that was predictive of
survival over time was basal Sat.O2. It suggests that
stability of PFTs might not reflect periods of disease
quiescence as previously thought, but rather the inability of
spirometry to detect ongoing disease activity and progres-
sion. However, patients’ number in our study is small and
change in FVC and DLCO over 12 months that have not
reached statistical significance (pZ 0.06) could be statis-
tically significant in a larger group of patients.
There are several potential sources of bias in our study.
First, the most severe form of IPF were excluded from the
study because if resting saturation was less than 90% on
room air, patients were not considered eligible for room air
6-MWT and were excluded from this study. These patients
performed 6-MWT with supplemental oxygen administered
using a threshold similar to that of other investigators in
this field45,46 and following published recommendations.47
Second, this is a retrospective analysis, with possible limi-
tations, and third it is a monocenter study with small
number of patients. The modest study sample size confers
low statistical power to detect significant survival indices.
While the size of our study population is limited, the fact
that each patient was cared with a standardized protocol
by a multi-disciplinary team in an experienced national
centre lends strength to our observations.
Only 3 patients had moderate pulmonary hypertension;
it seems unlikely therefore that this could affect our
results.
In conclusion, we demonstrated that distance walked in
6 min was independently related to mortality in IPF and
those patients walking <212 m had a significantly lower
survival rate than those walking farther as assessed by
KaplaneMeier survival curves. Our observations confer
validation (in a non-technical sense) to recently published
studies on prognostic significance of 6-MWT distance. An
important new information is that a downward trend in
distance walked at 12 months (when adjusted for baseline
value) is an independent determinant of survival and that
for each unitary decrease in meters walked at 12 months
observation, mortality increased by 1%.
Our data provide compelling argument for the clinical
use of 6-MWT in the evaluation of patients with IPF. The
simplicity of 6-MWT and its probable ability to assess
complex physiologic interaction and predict prognosis make
the 6-MWT an important tool for the management and
follow-up of patients with IPF. Furthermore, distance
walked during a 6-MWT give additional prognostic infor-
mation to previously described factors.
Survival is the most important outcome measure in
IPF, but requires large numbers of patients followed for
long periods of time. In IPF, 6-MWT distance is
a measurement of disease severity that can serve as
a surrogate outcome measurement and reflects the risk
of progression to death.
122 A. Caminati et al.Conflict of interest statement
All authors disclose any financial and personal relationships
with other people or organizations that could inappropri-
ately influence (bias) their work.Acknowledgements
The authors thank Dr. Simona Barlera for statistical advice.
References
1. American Thoracic Society. Idiopathic pulmonary fibrosis:
diagnosis and treatment: international consensus statement:
American thoracic society (ATS) and the European respiratory
society (ERS). Am J Respir Crit Care Med 2000;161:646e64.
2. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis:
clinical relevance of pathologic classification. Am J Respir Crit
Care Med 1998;157:1301e15.
3. Bjoraker JA, Ryu JH, EdwinMK, Myers JL, Tazelaar HD. Prognostic
significance of histopathologic subsets in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 1998;157:199e203.
4. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J,
Colby TV, et al. A histologic pattern of nonspecific interstitial
pneumonia is associated with a better prognosis than usual
interstitial pneumonia in patients with cryptogenic fibrosing
alveolitis. Am J Respir Crit Care Med 1999;160:899e905.
5. Nicholson A, Colby TV, du Bois RM, Hansell DM, Wells AU. The
prognostic significance of the histologic pattern of interstitial
pneumonia in patients with the clinical entity of cryptogenic
fibrosingalveolitis.AmJRespirCrit CareMed2000;162:2213e7.
6. Collard HR, King Jr TE, Bartelson BB, Vourlekis JS, Schwarz MI,
Brown KK. Changes in clinical and physiologic variables predict
survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med 2003;168:538e42.
7. Lettieri CJ, Nathan SD, Browning RF, Barnett S, Ahmad S,
Shorr AF. The distance-saturation product predicts mortality in
idiopathic pulmonary fibrosis. Respir Med 2006;100:1734e41.
8. Caminati A, Harari S. Which prognostic indicator should we use
for clinical practice in the initial evaluation and follow-up of
IIP: should we depend on PFT, HRCT or. what? Sarcoidosis
Vasc Diffuse Lung Dis 2005;22:S24e30.
9. King Jr TE, Tooze JA, Schwarz MI, Brown K, Cherniack RM.
Predicting survival in idiopathic pulmonary fibrosis: scoring
system and survival model. Am J Respir Crit Care Med 2001;
164:1171e81.
10. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM,
Wells AU. The relationship between individual histologic
features and disease progression in idiopathic pulmonary
fibrosis. Am J Respir Crit Care Med 2002;166:173e7.
11. King Jr TE, Schwarz MI, Brown K, Tooze JA, Colby TV,
Waldron Jr JA, et al. Idiopathic pulmonary fibrosis: relationship
between histopathologic features and mortality. Am J Respir
Crit Care Med 2001;164:1025e32.
12. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM,
Horrocks AW, Egan JJ. Pulmonary function in idiopathic
pulmonary fibrosis and referral for lung transplantation. Am J
Respir Crit Care Med 2001;164:103e8.
13. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH,
Colby TV, et al. Prognostic implication of physiologic and
radiographic changes in idiopathic interstitial pneumonia. Am J
Respir Crit Care Med 2003;168:543e8.
14. Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q,
et al. Prognostic value of desaturation during a 6-minute walktest in idiopathic interstitial pneumonia. Am J Respir Crit Care
Med 2003;168:1084e90.
15. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D,
Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneu-
monia: the prognostic value of longitudinal functional trends.
Am J Respir Crit Care Med 2003;168:531e7.
16. Agusti AG, Roca J, Rodriguez-Roisin R, Xaubet A, Agusti-
Vidal A. Different patterns of gas exchange response to exer-
cise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir
J 1988;1:510e6.
17. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal
exercise tests: reproducibility in fibrotic interstitial pneu-
monia. Am J Respir Crit Care Med 2005;171:1150e7.
18. Harari S, Caminati A. Idiopathic pulmonary fibrosis. Allergy
2005;60:421e35.
19. Spiro SG, Dowdeswell IRG, Clark TJH. An analysis of sub-
maximal exercise responses in patients with sarcoidosis and
fibrosing alveolitis. Br J Dis Chest 1981;75:169e80.
20. Agusti AG, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-
Roisin R. Mechanisms of gas-exchange impairment in idiopathic
pulmonary fibrosis. Am Rev Respir Dis 1991;143:219e25.
21. Chetta A, Aiello M, Foresi A, Marangio E, D’Ippolito R,
Castagnaro A, et al. Relationship between outcome measures
of six-minute walk test and baseline lung function in patients
with interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis
2001;18:170e5.
22. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative
systematic overview of the measurement properties of func-
tional walk tests used in the cardiorespiratory domain. Chest
2001;119:256e70.
23. Steele B. Timed walk tests of exercise capacity in chronic
cardiopulmonary illness. J Cardiopulm Rehabil 1996;16:
25e33.
24. Butland RJA, Pang J, Gross ER, Woodcock AA, Geddes DM. Two,
six, and 12 minute walking tests in respiratory disease. Br Med
J 1982;284:1607e8.
25. Cahalin LP, Mathier MA, Semigran MJ, Dec GW, DiSalvo TG. The
six-minute walk test predicts peak oxygen uptake and survival
in patients with advanced heart failure. Chest 1996;110:
325e32.
26. Mador MJ, Bozkanat E, Aggarwal A, Shaffer M, Kufel TJ.
Endurance and strength training in patients with COPD. Chest
2004;125:2036.
27. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F,
Fujita M, et al. Clinical correlates and prognostic significance
of six-minute walk test in patients with primary pulmonary
hypertension. Comparison with cardiopulmonary exercise
testing. Am J Respir Crit Care Med 2003;161:487e92.
28. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous
epoprostenol infusion in primary pulmonary hypertension.
Prognostic factors and survival. J Am Coll Cardiol 2002;40:
780e8.
29. Harari S, Caminati A, Bianchi A, Cassandro R, Schaumann A.
Walking distance on 6-MWT is a prognostic factor in idiopathic
pulmonary fibrosis. Proc Am Thorac Soc 2006;3:A102.
30. American Thoracic Society. Standardization of spirometry:
1994 update. Am J Respir Crit Care Med 1995;152:
1107e36.
31. Morris JF, Koski A, Johnson LC. Spirometric standards for
healthy non-smoking adults. Am Rev Respir Dis 1971;103:
57e67.
32. Goldman HI, Becklake MR. Respiratory function tests: normal
values at median altitudes and the prediction of normal
results. Am Rev Tuberc 1959;79:457e67.
33. Gaensler EA, Wright GW. Evaluation of respiratory impairment.
Arch Environ Health 1966;12:146e89.
34. American Thoracic Society. Single-breath carbon monoxide
diffusing capacity (transfer factor): recommendations for
6-MWT in pulmonary fibrosis 123a standard technique; 1995 update. Am J Respir Crit Care Med
1995;152:2185e98.
35. Dinakara P, Blumenthal W, Johnston R, Kauffman LA, Solnick PB.
Theeffect of correctionof anemia onpulmonarydiffusing capacity
with derivation of correction equation. Am Rev Respir Dis 1970;
102:965e9.
36. Crapo RO, Morris AH. Standardized single breath normal values
for carbon monoxide diffusing capacity. Am Rev Respir Dis
1981;123:185e9.
37. Sciurba F, Slivka W. Six-minute walk testing. Semin Respir Crit
Care Med 1998;19:383e92.
38. American Thoracic Society Statement. Guidelines for the
six-minute walk test. Am J Respir Crit Care Med 2002;166:
111e7.
39. Noble PW, Morris DG. Time will tell. Predicting survival in
idiopathic interstitial pneumonia. Am J Respir Crit Care Med
2003;168:510e1.
40. Schwartz DA, Helmers RA, Galvin JR, Van Fossen DS, Frees KL,
Dayton CS, et al. Determinants of survival in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med 1994;149:
450e4.
41. Gay SE, Kazerooni EA, Toews GB, Lynch III JP, Gross BH,
Cascade PN, et al. Idiopathic pulmonary fibrosis: predicting
response to therapy and survival. Am J Respir Crit Care Med
1998;157:1063e72.42. Harari S, Simonneau G, De Juli E, Brenot F, Cerrina J,
Colombo P, et al. Prognostic value of pulmonary hypertension
in patients with chronic interstitial lung disease referred for
lung or heart-lung transplantation. J Heart Lung Transplant
1997;16:460e3.
43. Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ,
et al. International guidelines for the selection of lung trans-
plant candidates: 2006 update e A consensus report from the
pulmonary scientific council of the International society for
heart and lung transplantation. J Heart Lung Transplant 2006;
25:745e55.
44. Lederer DJ, Arcasoy SM, Wilt JS, D’Ovidio F, Sonett JR,
Kawut SM. Six-minute-walk distance predicts waiting list
survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med 2006;174:659e64.
45. Stevens D, Elpern E, Sharma K, Szidon P, Ankin M, Kester S.
Comparison of hallway and treadmill six-minute walk tests. Am
J Respir Crit Care Med 1999;160:1540e3.
46. Chang JA, Curtis JR, Patrick DL, Raghu G. Assessment of
health-related quality of life in patients with interstitial lung
disease. Chest 1999;116:1175e82.
47. American Association for Respiratory Care. AARC clinical
practice guideline: exercise testing for evaluation of
hypoxemia and/or desaturation. Respir Care 2001;46:
514e22.
